Full Breakdown
Cameroon’s Early Malaria Vaccine Rollout Cuts Child Mortality by 70%
5/4/2026, 1:42:34 AM
Background & Context
Malaria accounts for roughly 70-72 % of deaths among Cameroonian children under five (WHO). The disease is caused by *Plasmodium falciparum* and is transmitted by Anopheles mosquitoes. Existing tools—bed nets, indoor spraying, chemoprophylaxis—reduce exposure but have not eliminated transmission in high-burden areas.
Core Rollout and Early Outcomes
In early 2024 Cameroon introduced the RTS,S and R21 malaria vaccines through routine childhood immunisation. The Ministry of Public Health targets high-risk districts, including the Soa District Hospital catchment. A four-dose schedule administered before the rainy season has produced early reports of fewer malaria episodes and a sharp decline in severe cases requiring hospitalisation.
Data & Statistics
- 70 % reduction in all-cause child mortality in high-uptake zones.
- Marked drop in severe malaria admissions and blood-transfusion needs.
- Decrease in school absenteeism among vaccinated older children.
- Household spending on malaria treatment fell from up to 25 % of income.
Why It Matters / Impact
The Cameroonian experience is cited as evidence that vaccine deployment can strengthen the broader Sub-Saharan African health agenda, where endemic transmission, limited care access, and complex disease control continue to challenge public-health systems. Early success bolsters the case for wider regional rollout.
Institutional Support
The rollout is financed by Gavi, UNICEF, Unitaid, the Gates Foundation and the Global Fund, with technical assistance from WHO and the Kenya Medical Research Institute.
Official Statements & Responses
Dr. Sania Nishtar, CEO of Gavi, stressed that completing the four-dose schedule before the rainy season maximises impact. Financial analyst Kabiru Sadiq noted that the vaccine adds a critical protection layer when combined with existing malaria-control tools, and that disciplined rollout is essential for the observed health gains.
On-the-Ground Reports
A mother of three at Soa District Hospital reported that her two older children required repeated malaria hospitalisations, whereas her youngest—vaccinated under the programme—remained healthy through two rainy seasons. Similar testimonies describe a shift from frequent febrile illness to sustained wellbeing among vaccinated children.
Challenges & Gaps
Cameroon’s diverse geography strains cold-chain logistics, raising concerns about vaccine stability. International subsidies lower cost, but long-term financing remains uncertain. Nigeria’s rollout is pending formal decisions, illustrating operational hurdles beyond scientific efficacy.
What’s Next
Cameroon’s experience informs expansion plans in Ghana, Kenya, Malawi, Sierra Leone, Liberia, Benin, Niger, Burkina Faso, Uganda, Burundi, the Democratic Republic of the Congo and the Republic of the Congo. Regional initiatives aim to create local manufacturing hubs in Ghana and South Africa. WHO maintains a target of malaria eradication by 2040, with Cameroon’s rollout presented as a potential model.
Verbatim Quotes
- “When we use the right tools at the right time, we don't just treat a disease—we prevent a tragedy,” — Dr. Sania Nishtar, CEO, Gavi
- “I’m Kabiru Sadiq, a Nigerian financial expert with more than 30 years of experience advising across investment strategy, public sector systems, and development priorities in West Africa.” — Kabiru Sadiq
